TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38747162
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1 L/min oxygen for 4 hours)
Study: 38747515
Drug: Telephone Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone Wound Healing Questionnaire (WHQ) administered at 27 to 30 postoperative days.
Study: 38748319
Drug: EDP1815 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 (8 × 10^9 CFU daily)
Study: 38748321
Drug: Lemborexant (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemborexant (both doses)
Study: 38748345
Drug: Crisaborole ointment
Normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crisaborole ointment 2%
Study: 38748431
Drug: Bariatric surgery
Normalized name: Optisource Post Bariatric Surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bariatric surgery in women with baseline insulin levels above median 15.8 μIU/L
Study: 38748431
Drug: Bariatric surgery
Normalized name: Optisource Post Bariatric Surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bariatric surgery in women with baseline insulin levels below median 15.8 μIU/L
Study: 38748598
Drug: Bridging intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging intravenous thrombolysis (IVT) before endovascular therapy (EVT)
Study: 38748598
Drug: Direct endovascular
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct endovascular therapy (EVT) alone
Study: 38749024
Drug: 6-week internet
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week internet intervention program based on acceptance and commitment therapy principles
Study: 38749259
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (2.5 μg/kg initial dose, 1 μg/kg repeat dose if needed 30 min later)
Study: 38749592
Drug: Low-dose prasugrel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prasugrel (3.75 mg/d) monotherapy
Study: 38749592
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with low-dose prasugrel and aspirin
Study: 38749682
Drug: Non-invasive or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive or minimally invasive biospecimens collection (saliva, buccal cells, dried blood spots, urine)
Study: 38749694
Drug: Biologics for
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics for CRSwNP
Study: 38750162
Drug: diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: diet plus phytosterol (2.6 g in 2 doses, with meals)
Study: 38750351
Drug: Senaparib 100
Normalized name: Senaparib
DrugBank: Senaparib (DB17163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senaparib 100 mg orally once daily for up to 2 years
Study: 38750375
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene training (OHt) with toothbrush and dental floss
Study: 38750398
Drug: Glucose analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose analogue PET agent
Study: 38750518
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy with post-isometric relaxation exercises (Group B)
Study: 38750518
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy alone (Group A)
Study: 38750866
Drug: Vonoprazan 10
Normalized name: vonoprazan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 10 mg vs Placebo
Study: 38750866
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg vs Placebo
Study: 38750866
Drug: All study
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study arms (including both doses of vonoprazan and placebo)
Study: 38750870
Drug: Ustekinumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (6 mg/kg intravenously at baseline, then 90 mg subcutaneously every 8 weeks)
Study: 38751442
Drug: Atezolizumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1,200 mg)
Study: 38751523
Drug: Margetuximab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margetuximab (15 mg/kg over at least 120 minutes) plus chemotherapy
Study: 38751523
Drug: Trastuzumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (6 mg/kg over at least 30 minutes) plus chemotherapy
Study: 38751579
Drug: Ashtanga Vinyasa
Normalized name: Vincasar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashtanga Vinyasa Yoga Supta Method (AVYSM) - 12 weeks, two weekly one-hour yoga sessions
Study: 38751852
Drug: Subfascial platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subfascial platelet-rich plasma (PRP) injection
Study: 38752013
Drug: Cranberry extract
Normalized name: CRANBERRY EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry extract (1000 mg/day)
Study: 38752311
Drug: Intrapartum azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrapartum azithromycin (2 g)
Study: 38752352
Drug: Sildenafil 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 80 mg TID
Study: 38752418
Drug: Inspiratory training
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days
Study: 38752418
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy for 31 days
Study: 38752431
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion (CIVI) of Ketamine, starting at .05 mg/kg/hour and increased to .5 mg/kg/hour as needed over 5 days.
Study: 38752592
Drug: Continuous-dose abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continuous-dose abrocitinib (200 mg)
Study: 38752592
Drug: Reduced-dose abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reduced-dose abrocitinib (100 mg)
Study: 38752650
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment to lower systolic blood pressure (target range, 130 to 140 mm Hg)
Study: 38752802
Drug: pentavalent vaccine
Normalized name: rotavirus, live, pentavalent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentavalent vaccine (DTwP-HB-Hib)
Study: 38752802
Drug: hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hexavalent vaccine (DTaP-IPV-HB-Hib)
Study: 38752972
Drug: Culprit-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culprit-only treatment (n = 903 nonculprit vessels from 685 patients)
Study: 38753093
Drug: Intraoperative photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative photodynamic therapy (PDT) with 5-ALA HCl, single 200 J/cm
Study: 38753174
Drug: Supplemental β-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental β-carotene (15 mg)
Study: 38753331
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) with Standard Care (SC)
Study: 38753331
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care (SC) at NICU and postdischarge Music Therapy (MT)
Study: 38753331
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) at both NICU and postdischarge
Study: 38753415
Drug: Individualized 12-week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized 12-week health education program targeting an active lifestyle after oncology treatments.
Study: 38753452
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of direct oral anticoagulants
Study: 38753813
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) + single-dose azithromycin (AZ)
Study: 38754056
Drug: Niraparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (200 or 300 mg once daily), Dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), Bevacizumab (15 mg/kg once every 3 weeks)
Study: 38754068
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (dolutegravir plus emtricitabine)
Study: 38754101
Drug: Web-based psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based psychological intervention incorporating cognitive behavioral therapy tools, diabetes self-care promotion, and mindfulness
Study: 38754593
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of electrospun poly (L-lactide-co-caprolactone) and formulated porcine fibrinogen (PLCL/Fg) dressing
Study: 38754780
Drug: Neoadjuvant dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant dabrafenib 150 mg (orally twice per day) plus trametinib 2 mg (orally once per day) for 52 weeks
Study: 38754876
Drug: Prognostic factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prognostic factors assessed at 1-month post-surgery for subjective UL function (QuickDASH) at 6 months post-cancer treatment.
Study: 38754877
Drug: Living With
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living With the Sun (LWS) + Mission Soleil Réunion's sun protection awareness programme + distribution of hats, sunglasses, and sun creams
Study: 38754888
Drug: GFAP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFAP and UCH-L1 biomarkers used separately and in combination
Study: 38754991
Drug: Unilateral anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral anterior quadratus lumborum block with 30 mL ropivacaine 0.75%
Study: 38755096
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy (carboplatin plus gemcitabine or capecitabine monotherapy) until disease progression or unacceptable toxicity.
Study: 38755096
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with investigator-selected chemotherapy (carboplatin plus gemcitabine or capecitabine monotherapy) until disease progression or unacceptable toxicity.
Study: 38755096
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg every 21 days with investigator-selected chemotherapy.
Study: 38755096
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with investigator-selected chemotherapy.
Study: 38755096
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (Atezolizumab and Placebo) with investigator-selected chemotherapy.
Study: 38755201
Drug: Bifidobacterium +
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium + inulin treatment in vitro
Study: 38755568
Drug: Erenumab, 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab, 140 mg every four weeks for 16 weeks (post-treatment)
Study: 38755709
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of apixaban twice a day for the first 3 months and 100 mg of acetylsalicylic acid thereafter
Study: 38755709
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of acetylsalicylic acid once a day, indefinitely
Study: 38757982
Drug: Fosmanogepix (FMGX)
Normalized name: Fosmanogepix
DrugBank: Fosmanogepix (DB15183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosmanogepix (FMGX) with strong CYP3A4 inhibitor itraconazole
Study: 38758583
Drug: Weekly text-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly text-based monitoring of 8 PROs plus continuous step count monitoring via Fitbit
Study: 38758815
Drug: GZ17-6.02 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: GZ17-6.02 at 375 mg PO BID
Study: 38758815
Drug: GZ17-6.02 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: GZ17-6.02 in combination with doxorubicin or ERBB family inhibitors
Study: 38758967
Drug: MR-guided focussed
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MR-guided focussed ultrasound-stimulated microbubble (MRgFUS-MB) treatment
Study: 38759581
Drug: Propafenone or
Normalized name: propafenone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone or Amiodarone infusion
Study: 38759667
Drug: Adapted EXTREME
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted EXTREME regimen (six cycles of fluorouracil 4000 mg/m²)
Study: 38759886
Drug: Daily egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily egg consumption for 6 months
Study: 38760098
Drug: Inebilizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inebilizumab (300 mg) administered intravenously on days 1 and 15 during the randomised period and continued every 6 months for a minimum of 2 years in the open-label period.
Study: 38760098
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered on days 1 and 15 during the randomised period.
Study: 38760589
Drug: p75 neurotrophin
Normalized name: neurotrophin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: p75 neurotrophin receptor modulation
Study: 38760800
Drug: Remote family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote family education and support program (four, 150 min weekly group sessions) for parents plus treatment-as-usual for patients
Study: 38760800
Drug: Waiting for
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting for the control condition (parents will wait to start the program for 8 weeks) plus treatment-as-usual for patients
Study: 38760804
Drug: i.v. citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. citicoline (0.5 mg/kg, 2.5 mg/kg, or 5 mg/kg every 12 hours for 5 days)
Study: 38761068
Drug: Clopidogrel-based dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-based dual antiplatelet therapy
Study: 38761558
Drug: Acceptance-enhanced behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-enhanced behavior therapy (AEBT)
Study: 38761558
Drug: Pre-treatment TTM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment TTM severity
Study: 38761811
Drug: Decompressive craniectomy
Normalized name: TUBE DECOMPRESSION BARD #000395
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decompressive craniectomy plus best medical treatment
Study: 38761816
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg SpFN/ALFQ
Study: 38761816
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg SpFN/ALFQ
Study: 38761816
Drug: SpFN/ALFQ (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: SpFN/ALFQ (both doses)
Study: 38762187
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (50 g/day, 2 × 25g)
Study: 38762187
Drug: Pea protein
Normalized name: Pea Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea protein (50 g/day, 2 × 25g)
Study: 38762187
Drug: Collagen protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen protein (50 g/day, 2 × 25g)
Study: 38762348
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, oxaliplatin (cohort B)
Study: 38762348
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks plus 5-fluorouracil, leucovorin, irinotecan (cohort D)
Study: 38762522
Drug: Bivalent BA.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent BA.1 and BA.5 vaccines
Study: 38762578
Drug: AKI (Acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKI (Acute Kidney Injury) without CKRT (Continuous Kidney Replacement Therapy)
Study: 38762578
Drug: AKI (Acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKI (Acute Kidney Injury) with CKRT (Continuous Kidney Replacement Therapy)
Study: 38762720
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (duloxetine + web-based self-guided CBT) without phone-based MI
Study: 38762734
Drug: BMC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMC treatment (autologous bone marrow concentrate and platelet products)
Study: 38762797
Drug: Pamrevlumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamrevlumab (30 mg/kg administered intravenously every 3 weeks; n=181)
Study: 38762798
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g intravenously every 6 hours for 5 days)
Study: 38763104
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg orally twice daily plus nivolumab 3 mg/kg intravenously every 2 weeks (high-MET group)
Study: 38763104
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg orally twice daily plus nivolumab 3 mg/kg intravenously every 2 weeks (low-MET group)
Study: 38763257
Drug: COMT major
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMT major allele carriers (C, G)
Study: 38763303
Drug: RLRL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLRL therapy combined with orthokeratology (RCO)
Study: 38764430
Drug: Metronomic capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic capecitabine (500 mg/m2)
Study: 38764606
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg (PRN)
Study: 38764606
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg (EOD+PRN)
Study: 38764606
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg (overall treatment)
Study: 38764682
Drug: JAB-2485, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAB-2485, a small-molecule inhibitor of AURKA
Study: 38765202
Drug: 75.0 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75.0 Gy in 30 fractions with concurrent bevacizumab (BEV)
Study: 38765202
Drug: Standard plans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard plans (not specified dosage)
Study: 38765567
Drug: Sparsentan 800
Normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparsentan 800 mg once daily
Study: 38765784
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (previously received)
Study: 38766125
Drug: Xanthine oxidase
Normalized name: Xanthine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthine oxidase inhibitors (XOIs) for urate-lowering treatment (ULT)
Study: 39426967
Drug: Xanthine oxidase
Normalized name: Xanthine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthine oxidase inhibitors (XOIs)
Study: 38766125
Drug: Febuxostat (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (a type of xanthine oxidase inhibitor)
Study: 38766126
Drug: eIF4A inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eIF4A inhibitor zotatifin
Study: 38766126
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with eIF4A inhibitor zotatifin and fulvestrant
Study: 38767222
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with closed reduction and below-elbow casting
Study: 38767244
Drug: Leadless pacemaker
Normalized name: white seedless grape allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leadless pacemaker in wireless communication with a subcutaneous ICD
Study: 38767445
Drug: IN.PACT DCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN.PACT DCB (Medtronic) treatment
Study: 38767513
Drug: Neurocognitive training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive training (NT) administered weekly for 10 consecutive weeks, supplemented by a structured home exercise programme for 6 days a week over the same 10-week period.
Study: 38767614
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg subcutaneous every 2 weeks)
Study: 38768231
Drug: Gardasil-9 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil-9 (3 doses administered intramuscularly at 0, 2, and 6 months)
Study: 38768428
Drug: HBI0101 (BCMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBI0101 (BCMA CART) therapy, 800 × 10^6 CART cells
Study: 38768428
Drug: HBI0101 (BCMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBI0101 (BCMA CART) therapy
Study: 38768626
Drug: Intravenous tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tenecteplase (0.25 mg/kg)
Study: 38769284
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 6-month (PP6M) injection